Mathew_2020_Comb.Chem.High.Throughput.Screen__

BACKGROUND: Multi-functional design of ligands emerged as new drug design paradigm of Alzheimer's disease (AD). Given the complexity of AD, the molecules showing dual inhibition of monoamine oxidase (MAO) and acetylcho- linesterase (AChE) with neuroprotective properties could prevent the progressive neural degeneration effectively. MATERIALS AND METHODS: Numerous studies documented that chalcone is a privileged structural framework for the inhibition of both MAO and AChE. RESULTS: The recent studies suggested that the development of chalcone candidates endowed with pharmacophores of FDA approved drugs may become an active molecules in the field of current AD research. CONCLUSION: The current perspective described the recent updates of chalcone moiety linked with the pharmacophores of flurbiprofen and rivastigmine hybrids as selective ChE/MAO-B inhibitors for the prophylactic agents for AD.